🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Registration opens on 1 June for the 7th International Lung Cancer Summit #ILCS25! Join our hosts, Alfredo Addeo MD & Solange Peters, and leading experts from around the world to explore the latest breakthroughs in thoracic oncology 🫁 🗓️ 26 September 2025 from 9:30AM CEST

National Cancer Centre Singapore - Proud of the Clinicians Representing NCCS and Singapore at ASCO 2025 Kevin Chua Melvin LK CHUA | FRCR, PhD, FASCO Rebecca Dent Stephanie Saw oncodaily.com/blog/asco-2025… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ASCO25

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥Genomic characterization of STAS in stage 1 EGFR-mutated NSCLC and prognostic implications 🎙️ Stephanie Saw 📌Poster Bd150, Abstr 8029 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

🌟#ASCO25 Meet-up👥 🎉Happy to meet Stephanie Saw

Grateful to catch up with friends, meet brilliant new colleagues, and soak up wisdom from giants who keep pushing oncology forward.Stephen V Liu, MD Sandip Patel MD FASCO Stephanie Saw Molly Li Herbert Loong, MBBS, FASCO David D. W. Lee, MBBS, FRCR. Benjamin Besse Kevin Chua Daniel Tan #ASCO25 #LCSM

Dr. Jamie Chaft with NEOADAURA at #ASCO25. Neoadjuvant osimertinib alone or with chemo vs neoadjuvant chemo in NSCLC. MPR only 2% with chemo, vs 25% with osi, 26% with osi/chemo. pCR 9% osi, 4% osi/chemo. EFS better for pts who MPR - curious how adjuvant osi contributed to EFS.

🔂The earlier the better? 🧪 Who needs more treatment? 🎯 How to improve cure? 👏👏👏👏 Lizza Hendriks #ASCO25

#ASCO25 Insightful discussion by Lizza Hendriks on perioperative strategies focusing on: ✔️subgroups of patients in need for escalation: nonPCR, PDL1neg, non-ctDNA clearance, p53(+) for EGFR ✔️ways to improve pCR rates: CRT, ICI combos, ADCs? Ami for EGFR+ #some #LCSM ASCO

#foodforthought 🍔🍕🍪🤔: the impact of infusion time of #ICIs is huge! ⏰ How many of our #immune checkpoint inhibitor clinical trials which #failed in the randomised setting may have done so ‘cos there was no stratification for this? #ASCO25 #CircadianRhythm Jordi Remon

EORTC Lung Group present at ASCO 2025! Excellent oral abstract discussions of Chair Jordi Remon and Secretary Lizza Hendriks EORTC

There is nothing more fulfilling (or is it just filling? 🥟🥡) than a truly #multinational 🇭🇰🇸🇬🇯🇵🇺🇸 #multidisciplinary #MDT before heading out to the airport as we ‘digest’ new knowledge acquired and say goodbye to #ASCO25. Molly Li Hidehito HORINOUCHI Yuji Uehara, MD Stephanie Saw

#ASCO25 most enjoyable one so far! Delighted to present our research, plan collabs and most importantly celebrate milestones with friends. Discussing data with people real-time in the congress beats listening online any day. Now time to combat jet lag 😵‍💫

Stoked to share my third editorial in JTO & JTO CRR this year! Dr Bironzo and I discuss SKIPPirr, which demonstrates significant reduction of Amivantamab-related IRR with oral dexamethasone prophylaxis. Definitely practice-changing, link is free till 26 Jul ddei5-0-ctp.trendmicro.com/wis/clicktime/…

肺癌学会プリセプターシッププログラムに参加してきました！ 刺激が多くモチベートされた二日間でした🔥 Thank you Stephanie Saw for taking the time out of your busy schedule to give such an inspiring and insightful lectures!!

Going to Japan for work is another level of 生きがい. Many thanks to 特定非営利活動法人 日本肺癌学会 for inviting me to speak at the preceptorship programme and Hidehito HORINOUCHI for hosting me. A pleasure to meet old friends and learn from new young enthusiastic ones too. 次回を楽しみにしています 😊

Huge thanks to Stephanie Stephanie Saw for her inspiring and informative talk with young lung oncologists in Japan! Her dedication and mentorship are truly impressive to me. This global collaboration and friendship are what I love about #LCSM

Always wonderful to meet #friends and #collaborators from around the region. Nice catchup with some of my 🇸🇬 colleagues Stephanie Saw Joe Yeong and Kevin Chua! Thanks so much for all your wonderful #hospitality, #support, #friendship and #collaborations! #LCSM

Activating mutations in EGFR gene has revolutionized management of #LungCancer, enabling development of TKIs. New review on strategies to optimize treatment: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… Alfredo Addeo MD Maxime Borgeaud Timothée Olivier, MD Jair Bar Kaushal Parikh Jill Feldman Xiuning Le MD PhD OncoAlert

A state-of-the-art Review on #EGFR mutant #NSCLC in the most prestigious journal in the world. A must-read for all thoracic oncologists! I enjoyed every single 📖 Congratulations Alfredo Addeo MD Xiuning Le MD PhD Stephanie Saw Giuseppe Banna and all co-authors, this will be the reference paper

Stephanie Saw from Singapore will present the latest advances in targeting HER2 and MET in NSCLC – highlighting how new strategies are tackling resistance mutations and expanding the reach of precision oncology. Come to the ILCS and gain fresh clinical insights ⬇️